Abstract
A correct identification of mold species causing human infections is of the utmost importance since treatment may differ depending on the infecting species. However, this is still a challenge in the current clinical practice, relying upon a morphological examination of acultured isolate.
In the first part of this PhD the focus was on Fusarium, a mold genus causing a wide variety of opportunistic human infections. In order to study the clinically relevant species diversity, the more than 300 Fusarium strains in the Belgian fungal culture collection BCCM/IHEM, mostly isolated from patients, were re-identified by multilocus DNA marker sequencing and phylogeny. The remaining
289 validated strains, comprising 40 different species, were of great value: (i) Analysis of the strain information revealed a species, i.e. Fusarium musae, of which it was not yet known that it caused human infections. (ii) A new species, closely related to Fusarium, was described, i.e. Pseudofusicolla biseptata. (iii) In vitro antifungal susceptibility testing was performed on the Fusarium dataset showing the importance of a correct species (complex) identification. (iv) The
Fusarium dataset was used to prove the feasibility of the MALDI-TOF mass spectrometry identification as opposed to the, often difficult, morphological identification.
In the second part of this PhD the focus was on the development of a new identification method for mold infections which is directly applicable on clinical samples and relies upon the detection ofspecies- and genus-specific peptides using tandem massspectrometry. Candidate peptides were selected according to a mass spectrometry based proteomics study. Accurate genus identification
of Fusarium and species identification of Aspergillus BCCM/IHEM collection material was possible and the new method was optimizedfor the analysis of clinical samples.
In the first part of this PhD the focus was on Fusarium, a mold genus causing a wide variety of opportunistic human infections. In order to study the clinically relevant species diversity, the more than 300 Fusarium strains in the Belgian fungal culture collection BCCM/IHEM, mostly isolated from patients, were re-identified by multilocus DNA marker sequencing and phylogeny. The remaining
289 validated strains, comprising 40 different species, were of great value: (i) Analysis of the strain information revealed a species, i.e. Fusarium musae, of which it was not yet known that it caused human infections. (ii) A new species, closely related to Fusarium, was described, i.e. Pseudofusicolla biseptata. (iii) In vitro antifungal susceptibility testing was performed on the Fusarium dataset showing the importance of a correct species (complex) identification. (iv) The
Fusarium dataset was used to prove the feasibility of the MALDI-TOF mass spectrometry identification as opposed to the, often difficult, morphological identification.
In the second part of this PhD the focus was on the development of a new identification method for mold infections which is directly applicable on clinical samples and relies upon the detection ofspecies- and genus-specific peptides using tandem massspectrometry. Candidate peptides were selected according to a mass spectrometry based proteomics study. Accurate genus identification
of Fusarium and species identification of Aspergillus BCCM/IHEM collection material was possible and the new method was optimizedfor the analysis of clinical samples.
Original language | English |
---|---|
Qualification | Doctor in Medical Sciences |
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 18 Dec 2015 |
Place of Publication | Brussel |
Publisher | |
Publication status | Published - 2015 |
Keywords
- fusarium species
- mass spectormetry